Obesity vs Type 2 Diabetes — Clinical Trial Comparison
Obesity
Chronic metabolic condition with excess body fat
VS
Type 2 Diabetes
Insulin resistance and progressive beta-cell dysfunction
Obesity and type 2 diabetes are intimately linked metabolic conditions — obesity is the single greatest risk factor for developing type 2 diabetes, and both conditions have been transformed by GLP-1 receptor agonist therapies. Their trial landscapes increasingly overlap as drugs like semaglutide and tirzepatide are tested for both weight loss and glycaemic control, while device-based approaches, metabolic surgery, and digital health interventions feature prominently in both.
Key Differences at a Glance
| Feature | Obesity | Type 2 Diabetes |
|---|---|---|
| Primary symptoms | Increased body weight, reduced mobility, fatigue, joint pain | Thirst, frequent urination, fatigue, blurred vision, slow healing |
| Key diagnostic criteria | BMI ≥ 30 (obesity), ≥ 40 (severe obesity), waist circumference | HbA1c ≥ 48 mmol/mol, fasting glucose ≥ 7.0 mmol/L, OGTT |
| Common complications | Cardiovascular disease, joint problems, sleep apnoea, fatty liver, certain cancers | Cardiovascular disease, neuropathy, nephropathy, retinopathy, foot ulcers |
| Link between conditions | ~80-90% of type 2 diabetes patients have overweight or obesity | Major risk factor; weight loss of 5-15% can induce diabetes remission |
| NICE first-line | Lifestyle intervention; GLP-1 RA (semaglutide) if BMI ≥ 35 with comorbidity | Metformin, lifestyle; GLP-1 RA or SGLT2i if cardiovascular/renal risk |
| Prevalence in UK | ~28% of adults (obese), ~64% (overweight including obese) | ~4.9 million diagnosed (~7% of adults) |
Clinical Trial Availability
| Trial Aspect | Obesity | Type 2 Diabetes |
|---|---|---|
| UK trials actively recruiting | 30-50 studies | 50-80 studies |
| Most common trial phase | Phase 2-3 | Phase 2-3 |
| Top interventions tested | GLP-1 RAs, GIP/GLP-1 dual agonists, amylin analogues, devices, digital health | GLP-1 RAs, SGLT2 inhibitors, novel insulins, islet cell therapy, digital health, devices |
| GLP-1/GIP trials | Major focus (semaglutide, tirzepatide, retatrutide, cagriSema) | Major focus (cardiovascular and renal outcome studies with GLP-1 RAs) |
| Surgery trials | Active (metabolic surgery comparisons, long-term outcomes) | Active (surgery vs medical management for remission) |
| Digital/lifestyle trials | Major focus (apps, wearables, behavioural interventions) | Active (digital therapeutics, remote monitoring, lifestyle interventions) |
Exciting Emerging Treatments
Obesity Trials
- Triple agonists (retatrutide) — GLP-1 + GIP + glucagon receptor targeting for greater weight loss
- CagriSema — combination of semaglutide + cagrilintide (amylin analogue)
- Oral GLP-1 receptor agonists — Rybelsus expansion and next-gen oral formulations
- Endoscopic procedures — endoscopic sleeve gastroplasty, gastric balloon improvements
- Gut microbiome interventions — personalised nutrition based on microbiome profiling
- Gene therapy for obesity — targeting leptin and melanocortin pathways
Type 2 Diabetes Trials
- Once-weekly insulins — icodec and efsitora alfa reducing injection burden
- Dual GIP/GLP-1 for diabetes — tirzepatide expanding diabetes indications
- Smart insulin — glucose-responsive insulin that activates only when needed
- Islet cell transplantation trials — stem cell-derived beta cells
- Remission induction trials — intensive weight loss approaches for T2D remission
- Artificial pancreas/closed-loop — automated insulin delivery for type 2 diabetes
💡 Not sure which trials you qualify for?
Use our Smart Matcher to answer a few questions about your condition and we'll find the most relevant trials for your specific situation — free, instant results.
Eligibility Differences
Obesity Trial Criteria
- BMI thresholds required (typically ≥ 30, or ≥ 27 with weight-related comorbidity)
- Weight history and previous weight loss attempts documented
- Exclusion of secondary causes of obesity (endocrine, genetic)
- Some trials require specific comorbidities (cardiovascular risk, sleep apnoea, NASH)
- Concurrent diabetes status affects trial eligibility (with vs without T2D)
Type 2 Diabetes Trial Criteria
- Confirmed type 2 diabetes diagnosis (HbA1c thresholds typically 7.0-10.0%)
- Diabetes duration documented (newly diagnosed vs established)
- Prior diabetes medications specified (metformin alone vs multiple agents)
- Renal function (eGFR) affects SGLT2 inhibitor trial eligibility
- Cardiovascular history determines cardiovascular outcome trial suitability
Type 2 Diabetes Trials
Find actively recruiting type 2 diabetes trials across the UK
Type 2 Diabetes TrialsFrequently Asked Questions
Can I join a clinical trial if I have both Obesity and Type 2 Diabetes?
It depends on the specific trial. Many trials allow comorbid conditions as long as the primary condition being studied is clearly dominant. Some trials explicitly exclude patients with significant overlapping conditions. Always check the eligibility criteria carefully and discuss with both the trial team and your specialist.
Which condition has more clinical trials available in the UK?
Both Obesity and Type 2 Diabetes have robust research pipelines with new studies opening regularly. The number of trials varies over time as new studies launch and others complete. Check our condition pages for the most current trial availability.
What should I consider when choosing between trials for these conditions?
Consider which condition impacts your quality of life most, what treatments you've already tried, the trial phase (earlier phases are more experimental), the time commitment involved, and whether the trial offers access to treatments not otherwise available. Your specialist can help you prioritise.